PHASEBIO PHARMACEUTICALS INC's ticker is PHAS and the CUSIP is 717224109. A total of 51 filers reported holding PHASEBIO PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $14,000 | -70.2% | 79 | 0.0% | 0.00% | – |
| Q2 2022 | $47,000 | -54.8% | 79 | 0.0% | 0.00% | – |
| Q1 2022 | $104,000 | -49.5% | 79 | 0.0% | 0.00% | – |
| Q4 2021 | $206,000 | -82.6% | 79 | -79.2% | 0.00% | – |
| Q3 2021 | $1,182,000 | +5.5% | 380 | +26.2% | 0.00% | – |
| Q2 2021 | $1,120,000 | -86.0% | 301 | -87.0% | 0.00% | – |
| Q1 2021 | $8,020,000 | -26.3% | 2,318 | -28.4% | 0.00% | – |
| Q4 2020 | $10,883,000 | -8.1% | 3,239 | -4.0% | 0.00% | – |
| Q3 2020 | $11,843,000 | +214.0% | 3,374 | +311.5% | 0.00% | – |
| Q2 2020 | $3,772,000 | -73.0% | 820 | -80.6% | 0.00% | – |
| Q1 2020 | $13,981,000 | +21.1% | 4,224 | +123.5% | 0.00% | – |
| Q4 2019 | $11,548,000 | +59.8% | 1,890 | +9.1% | 0.00% | – |
| Q3 2019 | $7,227,000 | +1474.5% | 1,733 | +4851.4% | 0.00% | – |
| Q2 2019 | $459,000 | – | 35 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Johnson & Johnson Innovation - JJDC, Inc. | 1,607,044 | $5,400,000 | 0.70% |
| NEA Management Company, LLC | 6,643,704 | $22,323,000 | 0.59% |
| DAFNA Capital Management LLC | 320,542 | $1,077,000 | 0.32% |
| Platform Technology Partners | 141,025 | $474,000 | 0.23% |
| Parkman Healthcare Partners LLC | 110,547 | $371,000 | 0.10% |
| Rock Springs Capital Management LP | 1,314,374 | $4,416,000 | 0.09% |
| GSA CAPITAL PARTNERS LLP | 140,341 | $472,000 | 0.08% |
| SABBY MANAGEMENT, LLC | 65,000 | $218,000 | 0.04% |
| Virtu Financial LLC | 28,821 | $97,000 | 0.01% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 127,600 | $429,000 | 0.01% |